Last reviewed · How we verify

anti-tumour necrosis factor α antibodies — Competitive Intelligence Brief

anti-tumour necrosis factor α antibodies (anti-tumour necrosis factor α antibodies) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody). Area: Immunology.

phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α (Tumor Necrosis Factor Alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

anti-tumour necrosis factor α antibodies (anti-tumour necrosis factor α antibodies) — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
anti-tumour necrosis factor α antibodies TARGET anti-tumour necrosis factor α antibodies Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α (Tumor Necrosis Factor Alpha)
Infliximab (Remicade) Infliximab (Remicade) University of California, San Diego marketed TNF-α inhibitor (monoclonal antibody) TNF-α (Tumor Necrosis Factor-alpha)
Golimumab treatment optimization. Golimumab treatment optimization. Hospital de Manises marketed TNF-α inhibitor (monoclonal antibody) TNF-α (Tumor Necrosis Factor-alpha)
SB5 SB5 Samsung Bioepis Co., Ltd. marketed TNF-α inhibitor (monoclonal antibody); biosimilar TNF-α (tumor necrosis factor-alpha)
Adalimumab and its biosimilars Adalimumab and its biosimilars Hanyang University Seoul Hospital marketed TNF-α inhibitor (monoclonal antibody) TNF-α (tumor necrosis factor-alpha)
Biosimilar Infliximab Biosimilar Infliximab Hikma Pharmaceuticals LLC marketed TNF-α inhibitor (monoclonal antibody) TNF-α (tumor necrosis factor-alpha)
Infliximab biosimilar Infliximab biosimilar Hanyang University Seoul Hospital marketed TNF-α inhibitor (monoclonal antibody) TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody) class)

  1. Merck Sharp & Dohme LLC · 3 drugs in this class
  2. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 2 drugs in this class
  3. Hanyang University Seoul Hospital · 2 drugs in this class
  4. Biocad · 1 drug in this class
  5. Children's Memorial Health Institute, Poland · 1 drug in this class
  6. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class
  7. Centocor, Inc. · 1 drug in this class
  8. Hikma Pharmaceuticals LLC · 1 drug in this class
  9. Hospital de Manises · 1 drug in this class
  10. Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). anti-tumour necrosis factor α antibodies — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-tumour-necrosis-factor-antibodies. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: